IG3018 not checked
Intelligem Therapeutics Australia Pty Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hyperuricemia, Hypouricemia, Renal
- Main trialPhase 1/2
- “This is a phase I/II clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.”In the company’s words, NCT06310967 on ClinicalTrials.gov
Other drugs for Hyperuricemia
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- Combined metabolic activatorsScandiBio Therapeutics AB · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- SHR4640Hengrui · Phase 2
- PRX-115Protalix · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jul 2026 | A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026